Research programme: erythrocyte-encapsulated therapeutics - EryDel

Drug Profile

Research programme: erythrocyte-encapsulated therapeutics - EryDel

Alternative Names: Erythrocyte-encapsulated PAL - EryDel; Erythrocyte-encapsulated phenylalanine ammonia-lyase - EryDel; PAL erythrocyte-encapsulated - EryDel; Phenylalanine ammonia-lyase erythrocyte-encapsulated - EryDel

Latest Information Update: 06 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EryDel
  • Developer EryDel; University of Rome; University of Urbino
  • Class Ammonia lyases
  • Mechanism of Action Phenylalanine ammonia lyase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Phenylketonuria

Most Recent Events

  • 05 Sep 2013 Preclinical trials in Phenylketonuria in Italy (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top